Annual revenue rose from KRW 15.1 billion in 2022 to KRW 17.4 billion in 2023 (up 14.8% year on year), KRW 18.1 billion in 2024 (up 4.3%) and KRW 20 billion in 2025 (up 10.5%), growing for three straight years from 2023 to 2025, with 2025 the largest year in the 2022 to 2025 window.
Operating profit moved from KRW 3.46 billion in 2022 to KRW 4.08 billion in 2023 (up 18.0%), then fell to KRW 1.86 billion in 2024 (down 54.5%) and turned into an operating loss of KRW 1.16 billion in 2025. The operating margin went from 23.5% in 2023 to 10.3% in 2024 and -5.8% in 2025.
Net income attributable to controlling shareholders fell from KRW 4.02 billion in 2023 to KRW 873 million in 2024 (down 78.3%) and became a net loss of KRW 409 million in 2025.
The company attributed the 2025 loss to a sharp rise in advertising costs for a subsidiary's new products and higher logistics and distribution costs from D2C expansion, while revenue growth came from new health supplement launches and wider customer acquisition.
The balance sheet strengthened, with the debt ratio falling from 59.9% in 2022 to 47.1% in 2025 and year-end 2025 total equity of KRW 33.1 billion against total liabilities of KRW 15.6 billion. Operating cash flow, however, dropped from KRW 7.79 billion in 2023 to an outflow of KRW 1.32 billion in 2025.
By quarter, Q3 2025 showed revenue of KRW 5.35 billion and an operating loss of KRW 68.68 million, and Q4 2025 revenue fell 14.2% quarter on quarter to KRW 4.59 billion with an operating loss of KRW 328 million, while attributable net income turned positive at KRW 105 million.
Q1 2026 revenue was KRW 4.88 billion with an operating loss of KRW 167 million, and Q2 2026 revenue was the highest of the last five quarters at KRW 5.38 billion, but the operating loss widened to KRW 249 million.
Q3 2026 revenue was KRW 4.83 billion, down 9.8% year on year, with an operating loss of KRW 398 million and an attributable net loss of KRW 312 million, a wider loss than a year earlier. Losses did not narrow even in quarters where revenue recovered, so cost structure remains the key variable for earnings recovery.